The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Class: Inotropic agent
- Injection 5 mg/mL (as lactate)
Positive inotropic agent with vasodilator activity.
Vd is 1.2 L/kg. 10 to 49% is protein bound. The t ½ is 4.6 min.
Several metabolites: N-glycolyl, N-acetate, O-glucaronide.
The t ½ is 3.6 h. The primary route is via the urine.
30 min to 2 h (dose-dependent)
There is increased Vd and decreased elimination t ½ .CHF
In CHF patients the mean elimination is t ½ of 5.8 h. Monitor hemodynamic response or drug level.
Indications and Usage
Short-term management of CHF in patients whose condition can be closely monitored and who have not responded adequately to digitalis, diuretics, or vasodilators.
Hypersensitivity to bisulfites.
Dosage and AdministrationAdults
IV Initial dose: 0.75 mg/kg bolus slowly over 2 to 3 min. Maintenance: 5 to 10 mcg/kg/min; additional 0.75 mg/kg bolus may be given 30 min after initiating therapy, not to exceed total daily dose of 10 mg/kg.
- Administer as supplied or dilute in 0.5% or 0.9% saline to a concentration of 1 to 3 mg/mL.
- Do not dilute in dextrose-containing solutions, although product may be injected into running dextrose infusion through Y-connector or directly into tubing. Do not infuse product and furosemide through same line.
- Use diluted solutions within 24 h.
Protect ampules from light. Store at room temperature.
None well documented.
Chemical interaction occurs slowly over 24 h when mixed directly with dextrose-containing solutions. Do not inject furosemide into IV line containing inamrinone; immediate precipitate forms.
Laboratory Test Interactions
None well documented.
Category C .
Safety and efficacy not established.
May cause allergic-type reaction in susceptible patients.
Supraventricular and ventricular arrhythmias have occurred.
Vigorous diuretic therapy may cause inadequate response to inamrinone therapy; liberalization of fluids may be needed. CVP monitoring has been advocated.
Dose may be reduced or drug may be discontinued if there are alterations in liver enzymes; if alterations occur with clinical symptoms, drug is discontinued.
Not recommended during acute phase.
Severe aortic or pulmonic valvular disease
More common in patients on prolonged therapy.
Arrhythmias, excessive hypotension.
- Instruct patient to avoid sudden position changes to prevent orthostatic hypotension.
- Advise patient to notify health care provider of shortness of breath and increased chest pain.
Copyright © 2009 Wolters Kluwer Health.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.